UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Heart (British Cardiac Society), ISSN 1355-6037, 11/2018, Volume 104, Issue 22, pp. 1859 - 1863
selective estrogen receptor modulators | Long QT syndrome | torsade de pointes | aromatase inhibitors | ventricular arrhythmias | sex steroid hormones | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prognosis | Humans | Middle Aged | Selective Estrogen Receptor Modulators - adverse effects | Long QT Syndrome - chemically induced | Long QT Syndrome - physiopathology | Young Adult | Heart Rate - drug effects | Aromatase Inhibitors - adverse effects | Long QT Syndrome - diagnosis | Aged, 80 and over | Adult | Female | Torsades de Pointes - diagnosis | Torsades de Pointes - physiopathology | Action Potentials - drug effects | Databases, Factual | Long QT Syndrome - mortality | Risk Assessment | Torsades de Pointes - mortality | Adverse Drug Reaction Reporting Systems | Risk Factors | Torsades de Pointes - chemically induced | Europe - epidemiology | Heart Conduction System - drug effects | Cardiotoxicity | Heart Conduction System - physiopathology | Adolescent | Aged | Tamoxifen - adverse effects | Heart | Testosterone | Cardiac arrhythmia | Dictionaries | Databases | Classification | Electrocardiography | Pharmacology | Breast cancer | Cancer therapies | Drug dosages | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
2.
Full Text
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Nature medicine, ISSN 1078-8956, 06/2020, Volume 26, Issue 6, pp. 808 - 809
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Betacoronavirus - pathogenicity | Arrhythmias, Cardiac - chemically induced | Coronavirus Infections - drug therapy | Humans | Pandemics - prevention & control | Pneumonia, Viral - drug therapy | Coronavirus Infections - physiopathology | Azithromycin - administration & dosage | Hydroxychloroquine - adverse effects | Arrhythmias, Cardiac - physiopathology | COVID-19 | SARS-CoV-2 | Pneumonia, Viral - complications | Coronavirus Infections - complications | Torsades de Pointes - diagnosis | Torsades de Pointes - physiopathology | Electrocardiography - methods | Betacoronavirus - drug effects | Torsades de Pointes - chemically induced | Electrocardiography - drug effects | Arrhythmias, Cardiac - virology | Hydroxychloroquine - administration & dosage | Pneumonia, Viral - physiopathology | Azithromycin - adverse effects | Oxygen - administration & dosage | Coronavirus Infections - virology | Arrhythmias, Cardiac - diagnosis | Viral Load - drug effects | Pneumonia, Viral - virology | Complications and side effects | Usage | Heart beat | Hydroxychloroquine | Arrhythmia | Azithromycin | Cardiac arrest | Dosage and administration | Drug therapy, Combination | Drug therapy | Health aspects | Risk factors | Index Medicus
Journal Article
Journal of pharmacological and toxicological methods, ISSN 1056-8719, 03/2017, Volume 84, pp. 111 - 127
Concordance | Field potential duration | Risk categorisation | Early afterdepolarization | Proarrhythmia | Multi-electrode array | Torsade de pointes | Human induced pluripotent stem cell-derived cardiomyocytes | Free concentration | Torsadogenic risk | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Cardiotoxins - toxicity | Induced Pluripotent Stem Cells - drug effects | Induced Pluripotent Stem Cells - physiology | Risk Assessment | Humans | Cells, Cultured | Torsades de Pointes - chemically induced | Action Potentials - physiology | Torsades de Pointes - pathology | Myocytes, Cardiac - drug effects | Myocytes, Cardiac - physiology | Torsades de Pointes - physiopathology | Action Potentials - drug effects | Risk assessment | Stem cells | Heart cells | Index Medicus
Journal Article
Cardiovascular research, ISSN 0008-6363, 7/2011, Volume 91, Issue 1, pp. 53 - 61
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Heart | Biological and medical sciences | Medical sciences | Cardiac dysrhythmias | Calcium Channel Blockers - adverse effects | Humans | Ether-A-Go-Go Potassium Channels - metabolism | Ion Channels - genetics | ERG1 Potassium Channel | Potassium Channel Blockers - adverse effects | Action Potentials | Dose-Response Relationship, Drug | Transfection | Sodium Channel Blockers - adverse effects | Computer Simulation | HEK293 Cells | Sodium Channels - metabolism | Torsades de Pointes - physiopathology | NAV1.5 Voltage-Gated Sodium Channel | Rabbits | Guinea Pigs | Risk Assessment | Models, Cardiovascular | Risk Factors | Torsades de Pointes - chemically induced | Torsades de Pointes - metabolism | Sodium Channels - drug effects | Ion Channels - antagonists & inhibitors | Ether-A-Go-Go Potassium Channels - antagonists & inhibitors | Patch-Clamp Techniques | Animals | Ion Channels - metabolism | Calcium Channels, L-Type - drug effects | Dogs | Calcium Channels, L-Type - metabolism | Kinetics | Index Medicus | Computer modelling | Risk prediction | Torsade-de-pointes | Pharmacology | Drug development | Original
Journal Article
Progress in biophysics and molecular biology, ISSN 0079-6107, 07/2019, Volume 144, pp. 61 - 76
Electrophysiology | Pharmacology | Finite element analysis | Computational modeling | Early afterdepolarizations | Torsades de pointes | Biochemistry & Molecular Biology | Biophysics | Life Sciences & Biomedicine | Science & Technology | Heart - physiopathology | Potassium - metabolism | Risk Assessment | Models, Cardiovascular | Humans | Pericardium - drug effects | Torsades de Pointes - chemically induced | Electrocardiography - drug effects | Torsades de Pointes - metabolism | Endocardium - pathology | Dose-Response Relationship, Drug | Heart Rate - drug effects | Torsades de Pointes - pathology | Pericardium - pathology | Phenethylamines - adverse effects | Heart - drug effects | Sulfonamides - adverse effects | Torsades de Pointes - physiopathology | Purkinje Cells - drug effects | Single-Cell Analysis | Purkinje Cells - pathology | Action Potentials - drug effects | Endocardium - drug effects | Drugs | Heart | Heart beat | Arrhythmia | Mandatory drug testing | Cardiac patients | Electrocardiogram | Electrocardiography | Dofetilide | Mechanical engineering | Index Medicus | early afterdepolarizations | torsades de pointes | electrophysiology | computational modeling | finite element analysis | pharmacology
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 06/2020, Volume 95, Issue 6, pp. 1213 - 1221
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pandemics | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Death, Sudden, Cardiac - prevention & control | Long QT Syndrome - chemically induced | Death, Sudden, Cardiac - etiology | Drug Monitoring - methods | Hydroxychloroquine - adverse effects | Risk Adjustment - methods | Torsades de Pointes - therapy | COVID-19 | SARS-CoV-2 | Ritonavir - adverse effects | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Drug Repositioning - ethics | Electrocardiography - methods | Long QT Syndrome - mortality | Anti-Infective Agents - adverse effects | Betacoronavirus - isolation & purification | Ritonavir - administration & dosage | Torsades de Pointes - mortality | Betacoronavirus - drug effects | Torsades de Pointes - chemically induced | Long QT Syndrome - therapy | Hydroxychloroquine - administration & dosage | Anti-Infective Agents - administration & dosage | Drug Repositioning - methods | Lopinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Personal protective equipment | Electrocardiography | Coronaviruses | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
7.
Full Text
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians
Current medical research and opinion, ISSN 0300-7995, 12/2013, Volume 29, Issue 12, pp. 1719 - 1726
Mitigation | Prevention | QT interval prolongation | Torsades de pointes | Drug-induced | Risk factors | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Cardiology. Vascular system | Heart | Biological and medical sciences | Medical sciences | Cardiac dysrhythmias | Pharmacology. Drug treatments | Long QT Syndrome - complications | Torsades de Pointes - etiology | Humans | Risk Factors | Male | PubMed | Long QT Syndrome - therapy | Long QT Syndrome - physiopathology | Sex Factors | Electrocardiography | Female | Torsades de Pointes - physiopathology | Torsades de Pointes - prevention & control | Index Medicus
Journal Article
Journal of cardiovascular electrophysiology, ISSN 1045-3873, 10/2016, Volume 27, Issue 10, pp. 1206 - 1213
QTc interval prolongation | QTc | torsade de pointes | hERG | efavirenz | HERG | Efavirenz | Torsade de pointes | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Reverse Transcriptase Inhibitors - blood | Humans | Torsades de Pointes - genetics | Male | Healthy Volunteers | Cytochrome P-450 CYP2B6 - metabolism | Potassium Channel Blockers - adverse effects | Action Potentials | Dose-Response Relationship, Drug | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Heart Rate - drug effects | Transfection | Time Factors | HEK293 Cells | Electrocardiography | Pharmacogenomic Variants | Adult | Benzoxazines - blood | Female | Torsades de Pointes - physiopathology | Potassium Channel Blockers - blood | Pharmacogenetics | Risk Assessment | Cytochrome P-450 CYP2B6 - genetics | Gene Frequency | Risk Factors | Torsades de Pointes - chemically induced | Benzoxazines - adverse effects | Genotype | Torsades de Pointes - metabolism | ERG1 Potassium Channel - metabolism | Homozygote | Phenotype | Adolescent | ERG1 Potassium Channel - antagonists & inhibitors | Antiviral agents | Cytochrome P-450 | Index Medicus
Journal Article
CNS drugs, ISSN 1172-7047, 6/2011, Volume 25, Issue 6, pp. 473 - 490
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Antipsychotics | Torsade-de-pointes | Sudden-death | QT-interval-prolongation | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Cardiology. Vascular system | Heart | Psycholeptics: tranquillizer, neuroleptic | Psychology. Psychoanalysis. Psychiatry | Cardiac dysrhythmias | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Neuropharmacology | Drug toxicity and drugs side effects treatment | Toxicity: cardiovascular system | Torsades de Pointes - epidemiology | Antipsychotic Agents - adverse effects | Death, Sudden, Cardiac - epidemiology | Humans | Risk Factors | Torsades de Pointes - chemically induced | Death, Sudden, Cardiac - etiology | Torsades de Pointes - physiopathology | Electrophysiologic Techniques, Cardiac - methods | Torsades de Pointes - complications | Complications and side effects | Tachycardia | Antipsychotic drugs | Prognosis | Cardiac arrest | Research | Health aspects | Risk factors | Index Medicus
Journal Article